Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report

Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report

Introduction: Chemoimmunotherapy is associated with promising activity in mesothelioma in phase II to III trials. Studies exploring this approach in patients ineligible for clinical trials are lacking. We assembled a cohort of patients receiving pemetrexed-based chemotherapy with durvalumab outside...

Full description

Saved in:
Bibliographic Details
Main Authors: Ibiayi Dagogo-Jack, MD, Aubrey Lasko, PharmD, Elizabeth A. Krueger, NP, Kitman Tsang, NP, Revati Rao, MD, Grace Hambelton, BA, Subba R. Digumarthy, MD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
Mesothelioma
Chemoimmunotherapy
Immunotherapy
Durvalumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001450
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items